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Abstract
Megalencephalic Leukoencephalopathy with subcortical Cysts (MLC) is a type of vacuolating leukodystrophy, which is
mainly caused by mutations in MLC1 or GLIALCAM. The two MLC-causing genes encode for membrane proteins of yet
unknown function that have been linked to the regulation of different chloride channels such as the ClC-2 and VRAC. To
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includes different transporters and ion channels known to be involved in the regulation of brain homeostasis, proteins
related to adhesion or signaling as several G protein-coupled receptors (GPCRs), including the orphan GPRC5B and the
proposed prosaposin receptor GPR37L1. Focusing on these two GPCRs, we could validate that they interact directly with MLC
proteins. The inactivation of Gpr37l1 in mice upregulated MLC proteins without altering their localization. Conversely, a
reduction of GPRC5B levels in primary astrocytes downregulated MLC proteins, leading to an impaired activation of ClC-2
and VRAC. The interaction between the GPCRs and MLC1 was dynamically regulated upon changes in the osmolarity or
potassium concentration. We propose that GlialCAM and MLC1 associate with different integral membrane proteins
modulating their functions and acting as a recruitment site for various signaling components as the GPCRs identified here.
We hypothesized that the GlialCAM/MLC1 complex is working as an adhesion molecule coupled to a tetraspanin-like
molecule performing regulatory effects through direct binding or influencing signal transduction events.
Introduction
Megalencephalic Leukoencephalopathy with subcortical Cysts
(MLC) is a rare type of leukodystrophy (1). Patients suffering
from MLC present macrocephaly, subcortical cysts and white
matter vacuolation, leading to epilepsy as well as motor and
cognitive impairments (2). MLC is caused by mutations in
either MLC1 (3) or GLIALCAM (also called HEPACAM) (4). These
genes encode for membrane proteins that form a complex
located at cell–cell junctions in brain perivascular astrocytic
processes or in Bergmann glia at the cerebellum (5). A reduced
number of patients (2%) do not harbor mutations in MLC1 or
GLIALCAM, suggesting the existence of other unknown disease
genes (6).
The functional role of the GlialCAM/MLC1 complex is
still unknown. Nevertheless, different proteins and activities
related to brain homeostasis are affected in a GlialCAM or
MLC1-dependent manner. Therefore, a role for these proteins
in neuronal ion/water homeostasis has been hypothesized.
For instance, depletion of MLC1 has been shown to reduce
VRAC activity in primary astrocytes (7,8). In addition, GlialCAM
and MLC1 have been shown to form a ternary complex with
the ClC-2 chloride channel (9). Also, co-expression of human
GlialCAM with ClC-2 changes the channel activity from inwardly
rectifying to an ohmic channel (10). Furthermore, the Na+/K+-
ATPase pump has been identified as a MLC1-interacting protein,
whereas the overexpression of MLC1 was observed to reduce
its activity (11). Finally, Cx43 has been identified as a GlialCAM
interacting protein (12) and MLC1 might influence Cx43 stability
at gap junctions in astrocytoma cells (13).
It is not clear how GlialCAM and MLC1 affect the activity of
different ion channels and transporters. It has been suggested
that they might influence signaling cascades by yet undefined
mechanisms (14). In this sense, recent work has shown that
the overexpression of human MLC1 in astrocytes decreases the
phosphorylation of extracellular signal-regulated kinases (ERK),
whereas primary astrocytes lacking MLC1 show an increase in
ERK phosphorylation (15).
In summary, although it is clear that GlialCAM/MLC1 pro-
teins regulate the activity of different ion channels and trans-
porters that play a role in neuronal brain homeostasis, the
mechanisms involved in this process remain unclear. Here, we
have determined the GlialCAM interactome from mouse brain
and analyzed its interaction with GlialCAM and MLC1. Among
the proteins identified as part of this network, we found spe-
cific G protein-coupled receptors (GPCRs), concretely the orphan
GPRC5B (16) and the proposed prosaposin receptor GPR37L1 (17),
which show a dynamic association with GlialCAM and MLC1
and regulate their surface levels. Based on the results of this
work, we propose a functional role for GlialCAM and MLC1
proteins.
Results
Identification of the GlialCAM interactome
For comprehensive identification of the GlialCAM interactome,
we performed affinity purifications (APs) with four different
antibodies specific for GlialCAM on membrane fractions pre-
pared from whole brains from adult rats, wild-type (WT) mice,
and Glialcam knockout (KO) mice (10). Membranes were solubi-
lized with the detergent buffer CL-47 plus 1 mm Mg2+, as earlier
experiments indicated that this detergent mixture was able to
maintain the interaction of GlialCAM with MLC1 and ClC-2, two
previously validated interactors (4,9). Total eluates of APs with
the anti-GlialCAM antibodies or with unspecific immunoglob-
ulins G (IgG) were analyzed by high-resolution nanoflow liquid
chromatography-tandem mass spectrometry (LC-MS/MS), which
provided data on both the identity and the amount of interacting
proteins. Two out of the four anti-GlialCAM antibodies purified
their target with high efficiency, allowing for a more detailed
analysis of the main target’s primary sequence. MS analyses
showed that GlialCAM, MLC1 and ClC-2 proteins were retained in
all APs with high efficiency, as reflected by the peak volume (PV)
values (see Materials and Methods) and the extensive coverage of
protein sequences (relative sequence coverage of 72, 53 and 74%,
respectively). The other proteins identified by MS were evaluated
for both their specifity and consistency of copurification with
the GlialCAM protein based on the quantitative data of pro-
tein amounts. For each protein, the consistency of enrichment
was evaluated with the different antibodies and its quantitative
correlation with the purified GlialCAM protein.
Together, these criteria defined a sharp-profiled proteome
(Fig. 1A for one GlialCAM antibody and Supplementary Material,
Fig. S1 for another GlialCAM antibody), identifying 21 proteins
as high-confidence constituents of the GlialCAM interactome in
the mouse brain. As summarized in (Fig. 1B), these constituents
comprise the aforementioned GlialCAM, MLC1 and ClC-2 and
previously identified transport/ion channels proteins interacting
with GlialCAM or MLC1. These include the gap junction protein
Cx43 (12,13), the glutamate transporters EAAT1/2 and the sodi-
um/potassium ATPase subunits alpha2 and beta2 (11,18). Other
proteins that mediate transport or have been related to chloride
channel function such as the bicarbonate transporter (NBCe1),
the glucose transporter (GLUT1), the sodium/calcium exchanger
1 (NCX1) or the protein tweety-homolog 1 were also identified.
In previous APs experiments using MLC1 antibodies, NBCe1 and
tweety-homolog 1 were also specifically co-purified with MLC1
(Fig. 1B).
Apart from transporters and ion channels, we identified pro-
teins related to cell adhesion or trafficking such as tetraspanin-
9 (CD9), Neuronal membrane glycoprotein M6-a/b (GPM6A/B)
or Syntaxin-1A/1B. Interestingly, CD9 was also identified in a
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Figure 1. Identification of the GlialCAM interactome. (A) Specificity map of the
GlialCAM interactome with one of the rabbit polyclonal anti-GlialCAM antibodies
used that detects a peptide from the C-terminus. Two-dimensional logarithmic
abundance-ratio plot illustrating the medians of PV ratios (rPV) obtained for any
protein in APs from rat membranes with the second anti-GlialCAM antibody used
versus IgG (x axis) and in anti-glialCAM APs from mouse membranes of wild-
type (WT) versus Glialcam KO animals (y axis). Gray bars (rPVs of 10) represent
the specificity threshold for this AB on either rPV scale and place specifically
purified proteins in the upper-right quadrant. Red dots denote finally annotated
GlialCAM constituents (B); black dots symbolize all other proteins. (B) List of
proteins belonging to the GlialCAM interactome classified according to their
assigned function. We indicate if they have been identified in AP using anti MLC1
antibodies and in MYTH screening using human MLC1 as a bait.
MLC1 as a bait, indicating direct interaction. GPM6A/B were also
identified in MLC1 APs (Fig. 1B).
Finally, three GPCRs were identified as components of the
GlialCAM interactome. One of these, the orphan GPRC5B (also
named RAIG2) was also identified in a MYTH using human MLC1
as a bait and also in APs using MLC1 antibodies. Therefore, it can
be considered a bona fide interactor. Interestingly, the two other
identified GPCRs (GPR37 and GPR37l1) belong to the same protein
family (19).
Interactions between GPCRs and GlialCAM/MLC1
GlialCAM and MLC1 have been related to signal transduction
changes, but the mechanisms involved in this process remain
unresolved (14,15). In this regard, we considered the identified
GPCRs as candidates for the signal transduction changes related
to GlialCAM/MLC1 and proceeded to characterize their inter-
action with MLC proteins. As MLC1 is only astrocytic (20), we
focused on GPRC5B and GPR37L1 and not on GPR37, which is
mainly expressed in oligodendrocytes (21).
We developed a polyclonal antibody which was able to
detect specifically GPRC5B by Western blot (Supplemen-
tary Material, Fig. S2A–B) and by immunofluorescence on
primary astrocytes (Supplementary Material, Fig. S2C). The
antibody was validated in siRNA and overexpression experi-
ments. For GPR37L1, we used commercially available antibodies
(see Materials and Methods) previously validated using Gpr37l1
KO animals (22).
Co-localization was tested and observed between MLC1 and
GPRC5B (Fig. 2A) or GPR37L1 (Fig. 2B) in primary cultures of astro-
cytes. We assessed colocalization with MLC1 and not with Glial-
CAM, as both proteins colocalize perfectly in astrocytes and we
have anti-MLC1 polyclonal and monoclonal antibodies directed
against the same MLC1 intracellular epitopes (23) and therefore,
are suitable for all experiments.
Proximity-ligation assays (PLA) in primary cultures revealed
close proximity between GPRC5B or GPR37L1 and MLC1
(Fig. 2C and D). Control experiments in WT cells without the
primary antibody or in astrocytes obtained from Mlc1 KO
animals (10) demonstrated the specificity of the PLA signal
(Fig. 2C and D).
At a tissular level, we could not detect a specific signal for
GPRC5B with the new antibody or with commercially available
ones. However, in purified gliovascular units (GVUs), a prepara-
tion more accessible to detect astrocytic endfeet proteins (24),
we could detect partial co-localization between GPRC5B and
MLC1 (Fig. 3A). GPR37L1 is mainly expressed in Bergmann glia
(25), where GlialCAM and MLC1 are also expressed. However,
co-localization between GPR37L1 and MLC1 in Bergmann glia
(Fig. 3B) was low. The fact that the co-localization between the
GPCRs and MLC1 was higher in primary cultures could indicate
that the accessibility of the antibodies against the GPCRs might
be limited in brain tissue preparations.
The ability of human GPRC5B or GPR37L1 to physically
interact in living cells with human GlialCAM or MLC1 was
then assessed in vitro by means of bioluminescence resonance
energy transfer (BRET) saturation assays. HEK293T cells were
co-transfected with a constant amount of either the GPRC5B-
Rluc or the GPR37L1-Rluc plasmids combined with increasing
concentrations of the MLC1-VFP (Fig. 4A) or GlialCAM-VFP
(Fig. 4B) plasmids. The interaction between GlialCAM and MLC1
(Fig. 4A) was used as positive control, whereas the lack of
interaction between LRRC8A [the main subunit of the VRAC
channel (26,27)] and either MLC1 (Fig. 4A) or GlialCAM (Fig. 4B)
was used as a negative control. A positive BRET signal was
detected when GPRC5B or GPR37L1 were co-expressed with
MLC1 (Fig. 4A) or with GlialCAM (Fig. 4B). The determination
of the BRET50 signal allowed to compare the strength of
interaction between GPR37L1 or GPRC5B with MLC1 versus the
interaction with GlialCAM. The BRET50 values for the interaction
of GPR37L1 with MLC1 and GPR37L1 with GlialCAM were 2.9 ±
0.9 (n = 5) and 2.6 ± 0.4 (n = 4), respectively, which were not
statistically different (P = 0.73). Similarly, the BRET50 values for
the interaction of GPRC5B with MLC1 and GPRC5B with GlialCAM
were 1.2 ± 0.3 (n = 4) and 0.7 ± 0.2 (n = 5), which were also not
statistically different (P = 0.19), indicating that GPCRs interact
with MLC1 and GlialCAM with similar avidity.
These results demonstrated that GPRC5B or GPR37L1 and the
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Figure 2. Localization of GPRC5B and GPR37L1 in primary cultures of astrocytes. (A) Representative images of immunostaining of MLC1 in green (left), GPRC5B in red
(middle) and merged stainings where the two proteins show a certain degree of colocalization at the plasma membrane (right, yellow) from cultured mouse astrocytes.
Scale bar, 20 μm (B) Representative confocal images of MLC1 (green), GPR37L1 (red), co-immunofluorescence labeling and DAPI staining (blue) in mouse cerebellar
primary astrocytes from wild-type (WT) pups. Scale bar, 75 μm. (C and D) PLA for protein interactions between MLC1 and GPRC5B (C) or GPR37L1 (D) in WT or Mlc1
KO cultured mouse astrocytes. Cells with only one primary antibody (MLC1 antibody) were used as negative controls. Scale bar, 20 μm. The number of PLA dots was
quantified using Image J. Data are mean ± standard error of the mean of three–four independent experiments. For statistical analyses, we performed a one-way analysis
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Figure 3. Localization of the identified GPCRs with MLC1 in brain slices. (A) The localization of GPRC5B and MLC1 in GVUs. Projection confocal plan of MLC1 (red) and
GPRC5B (green) immunolabeled GVUs purified from adult wild-type (WT) brain. Nuclei are labeled with Hoechst (blue) and blood vessel wall with Isolectin B4 (white).
Scale bar, 20 μm. (B) The localization of GPR37L1 and MLC1 in Bergmann glia. Representative confocal images of GPR37L1 (red), MLC1 (green) co-immunofluorescence
labeling and DAPI staining (blue), in cerebellar coronal sections of WT adult mice. Higher magnifications of boxed areas (dashed lines) in (A) and (B) are presented. Scale
bar, 20 μm.
our data obtained from slices and cell culture, they support the
existence of GPCRs-MLC protein complexes in living cells.
Lack of GPR37L1 increases MLC proteins in vivo
GPR37L1 is expressed exclusively in astrocytes and immature
oligodendrocytes within the brain, also being highly expressed
in Bergmann glia of the cerebellum (25). Gpr37l1 KO mice showed
no alteration of adult cerebellar layer cytoanatomy and organi-
zation and no signs of gliosis. At the functional level, animals
presented improved motor functions and advanced cerebellar
development (22). Based on the similarities of expression pat-
terns for GlialCAM, MLC1 and GPR37L1 together with the mild
phenotype of the KO mice, we reasoned that the analysis of
MLC proteins in Gpr37l1 KO mice may suggest direct effects of
GPR37L1 in MLC protein biology.
We first analyzed the consequences of the lack of GPR37L1
on MLC1 and GlialCAM protein levels. Western blot experiments
of cerebellum membranes indicated that both proteins were
upregulated in the Gpr37l1 KO (Fig. 5A). Because GlialCAM and
MLC1 stabilize ClC-2 at the plasma membrane (28), we then
measured ClC-2 protein levels. Similarly, ClC-2 protein levels
were increased in the KO animals in a significative manner
(Fig. 5A). In contrast, GPRC5B protein levels remained unchanged
(Fig. 5A).
An increased signal was observed in tissue samples from
KO animals when immunofluorescence experiments detecting
MLC1 and GlialCAM at the Bergmann glia were performed. How-
ever, MLC proteins showed a more dotted pattern compared with
WT signal (Fig. 5B). Similar results were observed for ClC-2 (Sup-
plementary Material, Fig. S3A). Quantification of the fluorescent
signal revealed increased amounts of MLC1 in Gpr37l1 KO mice
(Fig. 5B). Similarly, the fluorescent signal of MLC proteins was
increased in primary astrocyte cultures from the KO mice (Sup-
plementary Material, Fig. S3B). In contrast, the signal of GPRC5B
in astrocyte cultures from KO animals remained unchanged
(Supplementary Material, Fig. S3C).
To determine whether MLC1 subcellular localization was
altered in Gpr37l1 KO mice as the immunofluorescence stain-
ing suggested, we detected MLC1 by electron microscopy (EM)
immunogold experiments (Fig. 5C). These experiments showed
that the localization of MLC1 in Bergmann glia (Fig. 5Ca) or in
perivascular astrocytic processes was not affected (Fig. 5Cb).
Similarly, we assessed whether the expression of GPR37L1
and GPRC5B depends on MLC1. Western blot experiments
revealed that the total amount of GPR37L1 and GPRC5B was
the same in the brain and the cerebellum of Mlc1 KO mice
(Supplementary Material, Fig. S4A and B). Likewise, there was no
change in the subcellular localization of GPRC5B in the astrocytic
endfeet around blood vessels in Mlc1 KO mice (Supplementary
Material, Fig. S4C).
We conclude that the lack of GPR37L1 in mice upregulates
MLC protein levels without altering their localization. Moreover,
no change is observed for GPRC5B protein.
Knockdown of GPRC5B in primary astrocytes
downregulates MLC proteins
We next studied whether the lack of GPRC5B might influence
MLC proteins. GPRC5B has been described to be expressed in
neurons, oligodendrocytes and astrocytes (16). Gprc5b KO mice
display gliosis and axonal swellings in the cerebellum caused by
increased ROS (29,30). In order to avoid any secondary effect of
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Figure 4. Direct interaction of the human GPCRs with human GlialCAM or human MLC1 by bioluminescence resonance energy transfer (BRET) assays. Representative
BRET saturation curve between GPCRs and MLC1 (A) or GlialCAM (B) from 3 to 5 independent experiments. HEK293T cells were co-expressing a constant amount of
GPRC5b-Rluc or GPR37L1-Rluc in presence of increasing concentrations of MLC1-VFP or GlialCAM-VFP. The interaction between GlialCAM-Rluc and MLC1-VFP were
analyzed as positive control, and with human LRRC8A as negative control. Plotted on the x axis is the fluorescence value obtained from the VFP, normalized with the
luminescence value of the Rluc constructs 10 min after coelenterazine h incubation and the y axis the corresponding BRET ratio (x1000). mBU: mBRET units. Results
are expressed as mean ± standard error of mean.
of GPRC5B ablation on MLC proteins were therefore performed
on primary cultured astrocytes. For this purpose, we developed
adenoviral vectors expressing a shRNA against mouse Gprc5b (sh
Gprc5b) that were able to nearly deplete GPRC5B levels (Supple-
mentary Material, Figs S2B and C, and 6A). An adenoviral vector
expressing a scrambled shRNA was used as control.
In GPRC5B-depleted astrocytes, MLC1 and ClC-2 total protein
levels were significantly reduced. In contrast, GlialCAM and
LRRC8A protein levels were not altered (Fig. 6A). Because
our results have shown that GPRC5B interacts directly with
MLC1 and GlialCAM, we reasoned that GPRC5B ablation
could influence GlialCAM plasma membrane levels in the
absence of MLC1. GPRC5B depletion reduced GlialCAM levels
at the plasma membrane in Mlc1 KO astrocytes (Fig. 6B).
Immunofluorescence experiments indicated that GlialCAM
was internalized in Mlc1 KO astrocytes depleted of GPRC5B
(Fig. 6C), suggesting that GPRC5B may stabilize GlialCAM at
the plasma membrane. In these GPRC5B-depleted astrocytes,
complementation with an adenovector expressing human
MLC1 rescued GlialCAM localization at the plasma membrane
(Fig. 6C), in agreement with previous studies that indicated
that MLC1 also stabilizes GlialCAM (31). Hence, GPRC5B might
stabilize both MLC1 and GlialCAM at the plasma membrane
and thus, it may influence the activity of different chloride
channels that have been linked to the presence of Glial-
CAM and MLC1 in depolarizing (ClC-2) or hypotonic (VRAC)
conditions.
In agreement with this hypothesis, the ablation of GPRC5B
almost completely abolished the localization of ClC-2 at cell–cell
junctions in depolarizing conditions, with a drastic reduction
from 47 ± 2 to 7 ± 3 (n = 3 experiments, 108 cells counted,
∗∗∗P < 0.001) in GPRC5B depleted samples (Fig. 7A). Further-
more, whole cell patch-clamp experiments in rat astrocytes
demonstrated that GPRC5B knockdown decreased ClC-2 current
activation and prevented its change in rectification observed
in depolarizing conditions (Fig. 7B and C), as observed in the
measurements of the normalized current (Fig. 7C and D) and
the rectification index (Fig. 7E), respectively. Previous studies
using VRAC and ClC-2 inhibitors together with shRNA directed
against ClC-2 demonstrated that the chloride currents observed
in depolarizing conditions are mediated by ClC-2 associated with
GlialCAM and MLC1 (23).
Next, we measured VRAC activation by hypotonicity in
GPRC5B-depleted astrocytes (Fig. 7F–H). Reduction of GPRC5B
expression led to a dramatic reduction of VRAC current
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Figure 5. Expression and localization of MLC proteins in Gpr37l1 KO mice. (A) Representative Western blot analysis and densitometric quantification in whole cerebellar
extracts from wild-type (WT) and Gpr37l1 KO adult mice. Data are expressed in arbitrary units (rel.int.: relative intensity) as a ratio to the mean values obtained from
WT mice (unpaired t-test; ∗P < 0.035; ∗∗P < 0.007, n = 6, 7). (B) Representative confocal images of MLC1 (green), GlialCAM (red) co-immunofluorescence labeling and
DAPI staining (blue) in cerebellar sections of WT and adult mice (left). Scale bar, 20 μm. The quantification of MLC1 immunostaining intensity (right). Data are expressed
in arbitrary units as a ratio to the mean values obtained from WT mice (unpaired t-test; ∗∗P < 0.0070; n = 3). (C) At EM level, MLC1 post-embedding staining in Gpr37l1
KO showed immunoreactivity in the astrocyte–astrocyte junctions of protoplasmic (a) and perivascular (b) astroglial processes. AC, astrocyte; BV, blood vessel. Higher
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Figure 6. Characterization of GPRC5B depleted primary astrocytes. (A) Total protein levels of MLC1, GlialCAM, ClC-2 and LRRC8A were assessed by Western blot (left) in
extracts obtained from arrested astrocytes control or infected with shRNA against Gprc5b. β-actin was used as a loading control, and GPRC5B was detected to validate
the effect of the shRNA. The result shown is representative of four independent experiments. The quantification of these different experiments (right) revealed a
decrease in protein levels in the case of ClC-2 and MLC1. ∗P < 0.05 in the Student t-test of shRNA versus control. (B) Surface levels of GlialCAM in GPRC5B depleted
primary astrocytes from wild-type or Mlc1 KO mice were assessed by biotinylation and subsequent Western blot of the solubilized extract (sol), the supernantant of
the purification (SN) and the purification (P). Quantification of the biotynilated fraction (P) revealed a decrease in GlialCAM membrane protein levels only in Mlc1 KO
astrocytes. ∗P < 0.05 in the Student t-test of shRNA versus control. Calnexin was detected as a non-plasma membrane (ER) resident protein. (C) The misslocalization of
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Figure 7. Lack of GPRC5B affects ClC-2 and VRAC activation in depolarizing and hypotonic conditions. (A) Immunostainings of ClC-2 in Control or GPRC5B depleted
astrocytes treated with physiological or depolarizing solutions. GPRC5B depleted astrocytes showed a markedly reduced ClC-2 trafficking to cell–cell junctions in
depolarizing conditions (arrows). ∗∗∗P < 0.001 in one-way analysis of variance plus Dunnet multiple comparisons’ test versus the depolarizing control. (B–E) Reduced
activation in depolarizing conditions of the ClC-2 chloride channel in GPRC5B depleted astrocytes. (B) Representative whole-cell recordings from control and GPRC5B-
depleted rat astrocytes showing ClC-2 currents evoked by voltage pulses (from −120 to +50 mV) in both physiological and depolarizing conditions. The protocol applied
is depicted on the right. (C–E) Current-voltage relationships show the previously described increase in ClC-2 currents when astrocytes are treated with a depolarizing
solution and a change in the rectification index. In GPRC5B-depleted astrocytes, however, this increase in the current amplitude is much smaller and no changes in
the rectification index can be observed. Quantification of the current measured at −120 mV in both control and GPRC5B-depleted astrocytes can be seen in (D) and
changes in the rectification index are depicted in (E). Whole-cell currents shown in (C) and (D) are normalized by cell capacitance. ∗P < 0.05, ∗∗P < 0.01. The number
of experiments is Control phys = 20, Control depolarizing = 14, sh Gprc5b phys = 9, shGprc5b = 11. (F–H). (F) Representative whole-cell recordings from control and
GPRC5B-depleted rat astrocytes showing VRAC currents evoked by voltage pulses (from −80 to +80 mV) before and after 5 min of hypotonic stimulation. The protocol
applied is depicted in the middle. (G and H) Current-voltage relationships showed that current activation upon hypotonicity was not statistically significant in GPRC5B-
depleted astrocytes and VRAC currents from these cells were much smaller when compared with those of control astrocytes. Quantification of the current measured
at +80 mV can be seen in (H). Whole-cell currents shown in (G) and (H) are normalized by cell capacitance. ns, not significant, ∗P < 0.05, ∗∗P < 0.01. The number of
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Figure 8. Depolarization and hypotonicity dynamically modulate the interactions between MLC1 and GPCRs. (A) The interaction of MLC1 and the GPCRs in depolarizing
conditions. Astrocytes were treated with physiological or depolarizing solutions for 4 h, and then PLA between MLC1 and GPRC5B (left) or GPR37L1 (right) was assessed.
The number of PLA positive dots was normalized by the negative control and quantified using Image J. Data are mean ± standard error of the mean of three-four
independent experiments. ∗P < 0.05 in the Student t-test of depolarizing versus physiological conditions. (B) The interaction between GPRC5B and MLC1 protein
measured by PLA increased by hypotonicity. Wild-type (WT) or Mlc1 KO mouse cultured astrocytes were treated with physiological or hypotonic solution for 15 min,
and then PLA assay between GPRC5B and MLC1 was performed. Assays were performed with mouse monoclonal anti-MLC1 and rabbit polyclonal anti-GPRC5B. Mlc1
KO mouse astrocytes were used as negative control. Data analyses were from three independent experiments and were corrected subtracting the signal of the negative
control. ∗∗P < 0.001 in two-tailed Student t-test. (C) Model of the interplay between MLC proteins and two of the GPCRs identified in the GlialCAM interactome. In this
model, GlialCAM and MLC1 are negatively and positively regulated by GPR37L1 and GPRC5B, respectively. The interaction between the GPCRs and MLC proteins might
activate signal transduction cascades previously linked to Mlc1 or these GPCRs (such as cAMP, ERK1/2, Calcium or RhoA), which will regulate different transporters and
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Depolarization and hipotonicity modulates
GPCRs-MLC1 protein interaction
The above results suggested that the lack of GPR37L1 increases
MLC proteins levels, whereas the opposite was observed for the
lack of GPRC5B. This suggests that these GPCRs may interact
with MLC proteins in a dynamic manner. Previous studies
indicated that the interaction between GlialCAM/MLC1 and ClC-
2 in primary cultured astrocytes was dynamically regulated,
and it was observed on depolarizing conditions (23).
Then, we compared the interaction between GPRC5B or
GPR37L1 with MLC1 in physiological versus depolarizing
conditions in primary astrocyte cultures. PLA indicated that
the interaction between MLC1 and GPRC5B was increased
in depolarizing conditions whereas the interaction between
GPR37L1 and MLC1 was decreased (Fig. 8A). Therefore, these
experiments suggested that in depolarizing conditions GPRC5B
might be needed for signal transduction responses in a
GlialCAM/MLC1-dependent manner.
Subsequently, we assessed whether the interaction between
MLC1 and GPRC5B also varies in hypotonic conditions perform-
ing PLA. We observed that the interaction between both proteins
increased under hypotonic conditions (Fig. 8B).
Discussion
GlialCAM and MLC1 are two membrane proteins linked to a
human genetic disease (MLC) and whose biological functions are
poorly understood. Previous studies suggested that they might
have a role in astrocyte ion/water homeostasis by influencing
different ion channels and transporters. In this respect, a direct
interaction after astrocyte despolarization has been observed
with the chloride channel ClC-2 and it has also been shown
to influence VRAC chloride channels and regulatory volume
decrease after astrocyte osmotic swelling in an indirect man-
ner. In addition, it has been shown that the overexpression of
MLC1 downregulates intracellular signaling pathways control-
ling astrocyte activation and proliferation. In order to get more
insights into the biological role of GlialCAM and MLC1, we have
identified GlialCAM-interacting proteins and their association
with MLC1 by means of immunoprecipitation and MYTH exper-
iments. Our results revealed that GlialCAM forms a network of
∼20 proteins.
Within this proteome there are different proteins, some of
them previously identified (such as ClC-2, Cx43 or Na+/K+-
ATPase), which are related to ion or substrate transport and are
involved in the homeostasis of the extracellular media during
neuronal activity. Neuronal activity in the central nervous sys-
tem leads to an increase of potassium in the extracellular space
(32). This increase is rapidly buffered by neighboring astrocytes
through different molecular mechanisms, including the activity
of pumps, transporters and ion channels. One of the most impor-
tant processes contributing to potassium clearance is its uptake
by astrocytes mediated by the Na+/K+-ATPase (33). Moreover,
the ATPase is activated by intracellular increases in sodium, as
occurs in astrocytes during neuronal activity because sodium-
coupled glutamate transporters, mainly EAAT2 (or GLT-1) and
EAAT1 (or GLAST), remove neurotransmitters from the extracel-
lular media. Potassium may also enter into astrocytes through
potassium channels, mainly Kir4.1 (34). Potassium would diffuse
to neighboring astrocytes through gap junctions [composed by
connexins 30 and 43 (Cx30 and Cx43)] (35,36) in a process that has
been defined as spatial buffering (37,38). In addition, potassium
can be accumulated inside astrocytes, which is balanced by a
parallel transport of chloride to maintain electroneutrality (39).
In this case, it has been suggested that chloride might enter
astrocytes through ClC-2 chloride channels in association with
GlialCAM/MLC1 proteins (10). Within other proteins belonging
to the same group of transporter/ion channels, it is interesting
to mention the sodium-driven bicarbonate transporter (NBCe1).
Astrocytes contribute to the reacidification or basification of the
extracellular media during neuronal activity, partly through the
activation of NBCe1 (40).
The results presented here suggest that GlialCAM/MLC1 form
a protein scaffold for different transporters and ion channels
involved in neuronal homeostasis. Previous work has shown that
GlialCAM is able to target ClC-2 to glial junctions and modify
its gating properties (9). It remains unknown if GlialCAM is also
able to modify the functional properties and the localization of
the identified proteins. Hence, MLC disease could be caused by
impaired activity of some of the proteins found in the GlialCAM
interactome.
On the other hand, GlialCAM and MLC1 have been shown to
influence intracellular signaling pathways controlling astrocyte
activation and proliferation. Several proteins have been identi-
fied related to cell signaling within this proteome, such as three
different GPCRs (GPR37, GPR37L1 and GPRC5B), a tetraspanin
(CD9) (41) and the four transmembrane domain proteins Gly-
coprotein M6A and M6B (42,43). Considering the role played by
GPCRs, we hypothesize that some of the signaling pathways
involving MLC proteins might be caused by the activity of these
GPCRs.
Within the identified GPCRs, GPR37 and GPR37L1 are part of
the rhodopsin (Class A) family, specifically within the endothelin
B receptor-like peptide family (44–47). Both GPCRs are highly
expressed in the central nervous system. GPR37 is mainly
expressed in oligodendrocytes, whereas GPR37L1 is mainly
expressed in astrocytes with higher levels in the Bergmann
glia of the cerebellum. Studies with KO mice have shown that
GPR37 regulates negatively oligodendrocyte differentiation and
myelination (21), and that GPR37L1 participates in regulating
the development of neuronal and glial cells in the cerebellum
(22). Several groups have proposed that prosaposin and derived
prosaptides could bind to these GPCRs and activate them, but
in vitro studies with induced expression of both proteins have
so far failed to conclusively prove that these are the cognate
ligands (17,19,48–50). It has been indicated that GPR37 and
GPR37L1 are coupled to Gαi/o, which will inhibit adenylate
cyclase. Thus, the lack of these GPCRs results in increased cAMP
levels and Epac-dependent activation of MAPK cascade, which
leads to an increase in phospho-ERK1/2 (21,51). In this sense,
Mlc1 KO cells also show an increase in ERK phosphorylation
and its expression is also linked to astrocyte differentiation.
GPRC5B belongs to the family C group IV (metabotropic gluta-
mate receptor-like receptor) of GPCRs (16). GPRC5B is expressed
ubiquitously, particularly in the brain, mostly in the cerebellum,
adipose tissue and placenta (29). It is subcellularly localized at
the plasma membrane, Golgi and exosomes (52). GPRC5B has
been implicated in neuronal cell-fate determination, cerebellar
motor learning, obesity and inflammation (53–56). There is not
a known ligand neither a G protein coupled for GPRC5B, but
it seems to recruit the Src-family kinase Fyn through the SH2
domain during its activation, and the activity of Fyn regulates
inflammatory responses via NF-kB signaling (53,57). Considering
MLC, it has been found that in astrocytoma, the overexpression
of MLC1 inhibit the activation of IL-1β-induced inflammatory
signals (pERK, pNF-kB) that, conversely, were abnormally upreg-
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Thus, considering previous data and the present work, we
suggest that these GPCRs could participate in the signaling
role previously assigned to GlialCAM and MLC1 (Fig. 8C). First,
we have observed that the lack of GPR37L1 upregulates Glial-
CAM and MLC1 whereas the lack of GPRC5B downregulates
it, influencing ClC-2 and VRAC activity. As GPRC5B interacts
more with MLC1 in depolarizing and hypotonic conditions, the
activity of GPRC5B might be important in metabolic processes
related to changes in the ionic composition. In contrast, we
hypothesize that signaling through GPR37L1 might be related to
differentiation processes. Although future research is needed to
understand how GlialCAM and MLC1 modulate GPCR-associated
signaling processes, taking into account that they interact in
vitro, it is possible that they might regulate the activation of the
GPCRs through lateral interactions.
Although the exact role played by GlialCAM and MLC1 is still
unknown, this work has revealed that the role played by MLC1 is
very similar to the work performed by tetraspanins. Tetraspanins
are transmembrane proteins that span the plasma membrane
four times and that associate with other tetraspanins by homo-
and heterooligomerization (59). It has been described in many
cases that they form a tight complex with a single-pass trans-
membrane protein belonging to the immunoglobulin (Ig) super-
family (60). For instance, the tetraspanin CD81 is associated with
CD19 (61) or the tetraspanin CD9 with EWI-2 (62). Moreover, these
molecules can simultaneously associate laterally at the plasma
membrane with numerous integral membrane receptors, mod-
ulating their functions and organizing discrete, dynamic plasma
membrane compartments (63). Within these partners, there are
GPCRs (64) or other cytoplasmatic signaling mediators (65). They
might also regulate the trafficking and biosynthetic processing
of these partners (66). Considering MLC1, although the sequence
homology to tetraspanins is very low (∼20%), it passes the mem-
brane eight times, but biochemical studies indicate that each
four transmembrane domains can be considered as a duplicate
(6). As tetraspanins, MLC1 also oligomerizes with himself and
forms a tight complex with GlialCAM, a single-pass transmem-
brane domain of the Ig family (4). Here, we have also identified
the tetraspanin CD9 as a protein forming part of the GlialCAM
interactome and a direct interactor of MLC1. As tetraspanins,
MLC1 influence the trafficking of diferent partners, as it has been
shown for ClC-2 (9) or Cx43 (12). Finally, here we have shown that
GlialCAM and MLC1 might be interacting with different GPCRs in
a dynamic manner. Therefore, we propose that MLC1 biological
role is that of being a tetraspanin-like molecule. Final proof of
this hypothesis might need the determination of a 3D structure
of the GlialCAM/MLC1 complex.
Understanding the interrelationship between GlialCAM/MLC1
and the GPCRs found here could be crucial not only to the
development of therapies for MLC patients but also to unravel
the mechanisms conducted by astrocytes to control neuronal
homeostasis. In this sense, analyses of the posttranslational
modifications of the interactome proteins identified here in MLC
mice models as in the Glialcam KO, could provide novel insights
into regulatory mechanisms. It would be interesting to analyze
if the minor percentage of MLC patients without mutations in
GLIALCAM or MLC1 harbor mutations in any of the genes coding
for the GPCRs identified here.
Materials and Methods
Molecular biology
Plasmids presented herein were constructed using standard
molecular biology techniques employing recombinant PCR and
the Multisite Gateway System (Invitrogen). The integrity of all
cloned constructs was confirmed by DNA sequencing.
Animal procedures
The generation of Glialcam−/− and Mlc1−/− mice has been
previously described (10). Gpr37l1−/− mice has also been
previously characterized (22). For histological analyses of brains,
mice were perfused with 4% PFA/PBS and organs were postfixed
overnight. Mouse astrocyte cultures were performed from P0
to P2 mouse pups of the corresponding genotype as previously
described (31).
Membrane preparation
Fresh-frozen brains from mouse WT and Glialcam KO were
homogenized with a glass potter in sucrose buffer (320 mm
sucrose, 10 mm Tris, 2 mm MgCl2, 1 mm EGTA, protease inhibitors
(5×), pH 7.5; ca. 10 ml/g tissue) and centrifuged for 5 min at
1080 × g. The supernatant (SN) was collected and the procedure
was repeated with the pellet using a third of the sucrose buffer
volume. Both supernatants were combined and ultracentrifuged
(10 min at 200,000 ×g) to collect the crude membrane pellet.
The crude membrane pellet was resuspended in hypotonic
buffer (50 mm Tris/HCl pH 7.5) and allowed to lyse for 30 min
on ice (with gentle stirring). The membrane lysate was then
separated on a sucrose step gradient (10 ml 1.3 M sucrose and
10 ml 0.5 M sucrose, each in 10 mm Tris–HCl/1 mm Mg2+/pH
7.5) for 1 h at 200,000 × g. The interface band was collected,
diluted 3-fold with 20 mm Tris–HCl/1 mm Mg2+/pH 7.5 and
pelleted by ultracentrifugation. The pellets were resuspended
in a small volume of 10 mm Tris–HCl/1 mm Mg2+/pH 7.5 and
the protein concentration was determined by the Bradford
method.
Solubilization and AP
AP was carried out with CL47 supplemented with 1 mm Mg2+.
In addition to mouse WT and Glialcam KO membranes, a rat
brain membrane preparation was used. For each purification
experiment, 20 μg of immobilized antibody were incubated with
2 mg membrane solubilized with 1.6 ml CL47 (+1 mm Mg2+ and
4× protease inhibitors added). Solubilization was carried out at
a protein-detergent ratio of 1:8, incubated for 20 min on ice and
cleared by ultracentrifugation at 56,000 rpm/12 min (rotor Sorvall
S80-AT3; corresponding to a 200 S cutoff for solubilized particles).
After 2 h of incubation with the solubilisate antibodies were
washed with CL47 dilution buffer 1 mm Mg2+ (2 × 1 ml for 5 min)
and eluted with 2 × 7 μl non-reducing Lämmli buffer (100 mm
DTT added later).
MS sample preparation and LC-MS/MS analysis
The eluates from APs were shortly run on 10% SDS-PAGE gels
and silver-stained. Lanes were excised and split into two parts (>
and <50 kDa), each subjected to standard in-gel tryptic digestion.
Eluted peptides were vacuum-dried and redissolved in 13 μl 0.5%
trifluoroacetic acid prior to MS analysis.
For comprehensive LC-MS/MS analysis, peptides were loaded
on a C18 PepMap100 precolumn (5 μm; Dionex) and resolved on
an analytical 75 μm × 10 cm C18 column (PicoTipTM Emitter, 75
μm, tip: 8 ± 1 μm, New Objective; self-packed with ReproSilpur
120 ODS-3, 3 μm, Dr Maisch) using an aqueous-organic
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spectrometer (Thermo Scientific)]. Full spectra (with precursor
signals used for quantification) were acquired with a target
value of 500 000 and a nominal resolution of 60 000 (scan range
370–1700 m/z).
Up to five data-dependent collision-induced dissociation
(CID) fragment spectra per scan cycle were acquired in the
ion trap with a target value of 10 000 with dynamic exclusion,
preview mode for full precursor scans, charge state screening,
monoisotopic precursor selection and rejection charge state 1
enabled. Activation type was CID with default settings.
LC-MS/MS data were extracted and searched against the
UniProt Knowledgebase (mouse, rat, human and release 2013-09)
using the Mascot search engine (version 2.3.01; Matrix Science)
together with anti-GlialCAM AP datasets from a previous round
of experiments. For preliminary searches peptide mass tolerance
was set to 15 ppm. After linear shift mass recalibration the
window was narrowed to ± 5 ppm for final searches. Fragment
mass tolerance was set to 0.8 Da. One missed trypsin cleavage
and common variable modifications were accepted for peptide
identification. Proteins identified by only one specific MS/MS
spectrum or representing exogenous contaminations such as
keratins or Igs were eliminated.
Analysis of GlialCAM and MLC1 interaction partners
The set of GlialCAM-APs (total of 14) was quantitatively evalu-
ated together with an AP data set from an older experiment (pre-
vious study, 4 samples). A label-free evaluation pipeline similar
to (67) was used. Briefly, m/z features among LC-MS scans were
detected and their intensitied integrated (as intensity × reten-
tion time × m/z width = PV) using MaxQuant (Cox and Mann
2008, version 1.3). m/z-corrected features were then aligned
between different LC-MS/MS runs and assigned to the peptides
identified by Mascot using a home-written software tool with
mass tolerance set to 1.5 ppm and a time shift window of 1 min.
The resulting assignment showed an even distribution with very
high m/z precision and no obvious systematic error (symmetric,
no offsets from 0 in either dimension).
Based on the accurately assigned PVs, protein abundance
ratios (rPV) in purifications from WT versus control (IgG or
Glialcam KO) were determined using the TopCorr method (68).
Protein-specific peptide PVs were ranked across the evaluated
datasets by their consistency using pair-wise linear correlation
analysis (Pearson correlation). A maximum of six to a minimum
of two peptide PVs were then selected from the best correlating
PVs to calculate the abundance ratio as median of the respec-
tive peptide PV ratios (referred to as rPV). To ensure validity,
sequenced peptides with missed PV assignment were omitted
and a minimum of two peptide ratios with total assigned PVs of
80 000 units were required; if no PV could be assigned to a peptide
in the AP controls, the detection limit of the spectrometer (3000
PV units with the settings used here) was inserted as a mini-
mum estimate. Distributions of protein rPV values were plotted
for each sample pair to derive specificity thresholds. Proteins
were considered specifically co-purified when rPV (vs IgG) >
threshold (IgG) in both, rat and mouse, and no cross-reactivity
was indicated by rPV(vs KO) < threshold (vs KO). For each pro-
tein, the consistency of enrichment was evaluated with the
different antibodies as well as its quantitative correlation with
the purified target GlialCAM_Mouse [based on abundancenorm
values, (68)].
Finally, the LC-MS/MS data from previous Mlc1 AP experi-
ments were reprocessed and evaluated according to the same
improved procedures as described above. Because these datasets
did not include target KO controls, specificity could not be evalu-
ated with the same degree of stringency. Rather high thresholds
(factor 20–60) for purification rPVs versus IgG were therefore
applied.
MYTH screenings
A MYTH screening was performed with the biotech Dualsys-
tems, using the bait vector pBT3-Ste containing human MLC1.
A second screening was performed using the human brain
DUALmembrane cDNA library in the NubG-x orientation as
described (69).
Cell culture and transfection
Human embryonic kidney HEK-293T cells were grown at 37◦C
in an atmosphere of 5% CO2 in Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
1 mm sodium pyruvate, 2 mm L-glutamine, 100 U/mL strepto-
mycin, 100 mg/mL penicillin and 5% (v/v) fetal bovine serum.
The cells were seeded into six-well plates containing poly-D-
lysine-coated glass coverslips at ∼300 000 cells/well. Cells were
transiently transfected with the corresponding cDNA constructs
using TransfectinTM (Bio-Rad, Hercules CA, USA) and following
the manufacturer’s instructions.
Immunological procedures
For immunofluorescence staining, primary cells and tissue sec-
tions were fixed and processed as previously described (20,70).
The polyclonal rabbit antibodies used were the following: anti-
GlialCAM (1:100) (4), anti-MLC1 (1:100) (71), anti-ClC-2 (1:100) (9),
anti-LRRC8A (1:100) (A304-175-A, Bethyl antibodies) (15) and the
antibody developed in this work anti-GPRC5B against the peptide
(C)TIPTAPPSHTGRHHW, using the services provided by Eurogen-
tec. We also used a mouse monoclonal antibody that was devel-
oped against the mouse peptide sequence of the N terminus
of MLC1 (TREGQFREELGYDRM) (23) and a mouse monoclonal
specific for GPR37L1 (1:50 in mouse primary astrocytes, 1:100 in
mouse tissue sections, Mab Technologies, Cat. N. scB12). GPR37L1
and MLC1 co-immunostaining was performed in mouse primary
astrocytes from Gpr37l1 WT and KO pups (51), after fixation with
100% methanol at -20◦C for 20 min, permeabilizing with 0.1%
Triton X-100 and incubating for 1 h at room temperature in
blocking buffer containing 0.5% BSA, 0.3 M glycine (Merck, Cat#
104201) and 0.1% Tween-20.
For electron immunogold experiments, small samples of
Gpr37l1 cerebellum KO mice tissue were obtained and fixed
in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.12 m
phosphate buffer, and processed. They were cryoprotected
gradually in sucrose and cryofixed by immersion in liquid
propane. Freeze substitution was performed at −90◦C during
3 days in an Automatic Freeze Substitution System (AFS,
Leica); methanol containing 0.5% uranylacetate was used as
a substitution medium. Infiltration was carried out in Lowicryl
HM20 at −50◦C and then polymerized with UV light. Ultrathin
sections were collected, and when needed, processed for post
embedding immunostaining. For immunostaining, grids were
incubated with rabbit anti-MLC1 (1:10) or antisera. The binding
of the primary antibody was visualized by incubating with a
secondary antibody conjugated to 18 nm gold particles (British
BioCell, International).
In the western blot studies, astrocyte lysates and cerebellar







g/article/30/17/1649/6294512 by guest on 16 Septem
ber 2021
1662 Human Molecular Genetics, 2021, Vol. 30, No. 17
(20,72). The mouse GPR37L1 protein was detected with a goat
polyclonal antibody (1:500, Santa Cruz, Cat. N. sc-164532). β-actin
or α-tubulin proteins were used as a loading control.
To detect surface levels of GlialCAM, WT or Mlc1 KO mouse
astrocytes were cultured in 6 cm plates. They were washed 3
times with PBS-CM (PBS with 1 mm CaCl2 and 1 mm MgCl2). Sub-
sequently, the astrocytes were incubated on ice for 30 min in PBS-
CM containing 2 mg/ml EZ-LinkTM Sulfo-NHS-Biotin (Thermo
Scientific). After three washes with PBS-CM, they were quenched
for 10 min in PBS Ca/Mg containing 10 mm Lysine. After three
additional washes with PBS-CM, the cells were lysed in RIPA
buffer (50 mm Tris pH 8, 150 mm NaCl, 1% NP-40, 0.5% deoxy-
cholate, 0.1% SDS, 2 mm EDTA) containing protease inhibitors, for
1 h. After centrifugation for 15 min at 14 000 rpm, the lysate was
quantified using the BCA protein assay (Thermo Fisher). Then
2 mg of the solubilized extract in a total volume of 200 μl was
incubated with 100 μl of streptavidin agarose (Thermo Fisher)
O/N at 4◦C. After a brief centrifugation, the SN was taken and
the beads were washed three times with RIPA buffer. Biotinylated
proteins were eluted with LSB 1× for 15 min at 60◦C. Samples of
lysate, SN and eluate were analyzed by western blot. To confirm
that only membrane proteins were detected in the eluate, we
performed a western blot with antibodies to test for the protein
calnexin resident in the endoplasmic reticulum.
GVUs purification
GVUs were isolated from whole WT OF1 brains as previously
described (24). A selective filtration was performed to enrich
vessels of 20 to 100 am diameter (24). For immunostaining,
GVUs were plated on a glass slide coated with Cell Tak (Corn-
ing, Corning, NY, USA) and fixed in PBS/PFA 4% for 15 min at
room temperature. GVUs were immersed in the blocking solu-
tion (PBS/NGS 5%/Triton X-100 0.5%) for 1 h at room temperature
and incubated with primary antibodies and Isolectin GS-B4 (IB4)
diluted in the blocking solution 12 h at 4◦C. After 3 PBS washes,
slices or GVUs were incubated 2 h at room temperature with
secondary antibodies, rinsed in PBS and finally embedded in
Fluormount G. GVUs were analyzed using a 63X objective on a
confocal microscope.
Quantification of immunofluorescence and western
blot labeling
Quantitative analysis of immunofluorescence signals was per-
formed with the Imaris 5.0.2 software (Bitplane). Experiments
were carried out with tissue samples obtained from three mice
per genotype. Sections of similar size in similar regions were
chosen and analyzed. All measurements were performed with
the observer blind to the identity of the slides.
Quantification of western blot immunoreactive bands
was performed with the Chemidoc XRS+ imager and Image
Lab software (Bio-Rad). Experiments were carried out with
tissue extracts obtained from six to seven mice per genotype.
The intensity of each band was normalized to the intensity of
the corresponding α-tubulin band. The average values of each
experimental group were expressed in arbitrary units, as a ratio
to the mean values obtained from the WT groups.
Primary astrocyte culture, adenoviral transduction and
RNA interference
Rat primary quiescent astrocyte cultures were prepared as
described previously (20) and maintained in culture in the
presence of the mitotic inhibitor AraC for biochemical studies.
Dibutyryl-cAMP (dBcAMP) differentiated rat astrocytes obtained
as described elsewhere (73), were used for electrophysiological
measurements, because they express higher levels of ClC-
2 currents and are easier to patch. Immunofluorescence
experiments were performed on both types of cultures, with
similar results. The physiological solution was: (in mm) NaCl
122, KCl 3.3, MgSO4 0.4, CaCl2 1.3, KH2PO4 1.2, HEPES 25, Glucose
10 and it had pH 7.4. The osmolarity was 290–300 mOsm and was
adjusted with manitol using a vapor-pressure osmometer (Model
3320, Advanced Instruments). In the hypoosmolar solution
the osmolarity was adjusted to 180 mOsm/kg. Adenovirus
expressing HA-tagged MLC1, and the transduction of astrocytes
has been described previously (4). RNAi entry-clone (Gateway,
Invitrogen) vectors were prepared using the Block-it PolII
miR RNAi EmGFP or the Block-it PolII miR RNAi expression
vector kit following the manufacturer’s instructions. Entry
clones were recombined using LR clonase into the vector
pAdVDEST-CMV/V5. Adenoviruses were produced and titrated
using fluorescence microscopy detecting EmGFP, which is
expressed together with the shRNA, or detecting the viral protein
Ad-Hexon. The sequence of the oligo used to knock down
mouse GPRC5B expression was: shRNA Gprc5b (shRNA111): 5′
TGGACTGGACCTTCTTCCTCA 3′.
Proximity-ligation assays
Mouse cultured astrocytes seeded on 24 well coverslips were
treated with physiological, depolarizing (60 mm K+) or hypo-
tonic solutions and then were fixed with PFA 3%. Cells were
blocked with PBS1x/0.1% Triton X-100/10% FBS for 2 h, and then
incubated with the primary antibodies (Mouse monoclonal or
Rabbit anti-MLC1 antibody 1:100; Rabbit polyclonal anti-GPRC5B
antibody 1:100, Mouse monoclonal anti-GPR37L1 1:100) diluted
in blocking solution for 1 h. After 3 washes of 10 min with
blocking solution, cells were incubated with the anti-rabbit PLA
(+) and the anti-mouse PLA (−) probes (Sigma) diluted 1/5 in
blocking solution for 1 h in a 37◦C humid chamber. Cells were
washed twice with washing buffer A (Sigma) during 5 min. To
ligate the PLA probes, cells were incubated in ligation buffer
diluted 1/5 in water containing the ligase diluted 1/40 for 1 h in
a 37◦C humid chamber. After 2 washes with washing buffer A of
2 min, the amplification reaction was performed in ampli RED
buffer diluted 1/5 in water containing the polymerase diluted
1/80 for 100 min in a 37◦C humid chamber. Cells were washed
twice with washing buffer B during 10 min, followed by an
additional wash with washing buffer B diluted at 0.01% during 1
min. Finally, coverslips were mounted in DUOLINK DAPI medium
and images were acquired using a CellR olympus microscope.
To quantify the PLA signal, images were analyzed using
ImageJ (74). First, nuclei were identified and substracted. Then,
images were transformed to 8 bit and converted to binary
images using the threshold setup. The number of dots/particles
corresponding to the PLA signal was quantified using the
analyse particle command of the ImageJ submenu, considering
that the size (2∧) of the particles should be bigger than 5. For
each image, we determined the number of dots divided by the
number of nuclei.
BRET experiments
HEK293T cells were transfected with a constant amount of
GPRC5B-Rluc (200 ng), GPR37L1-Rluc, GlialCAM-Rluc or LRRC8A-
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Equal DNA ratios were maintained with co-transfection or the
empty vector pCDNA3.1, which equilibrated the total amount
of transfected DNA. Forty-eight hours post-transfection, cells
were washed three times with PBS, detached and resuspended
in Hanks balanced salt solution (Thermo Fisher Scientific).
An aliquot was used to determine the protein concentrations
via the BCA assay, to control the total amount of protein
used in the assay. Accordingly, cells were diluted to a density
corresponding to a final protein concentration of 600 ng/μl. Cell
suspensions (corresponding to 20 μg protein) were distributed in
duplicates into white and black 96-well microplates (#3600 and
#3650; Corning, Stockholm, Sweden) for BRET1 and fluorescence
measurements, respectively. The substrate, h-coelenterazine
(Molecular Probes, Eugene, OR, USA) was added at a 5 μM final
concentration. After 1 min (BRET1) and 10 min (Rluc total), the
signals were measured using the ClarioSTAR microplate reader
(BMG Labtech, Ortenberg, Germany) through the sequential
integration of signal detection at 475 nm (445–505 nm) and 530
nm (500–560 nm). The net BRET1 ratio was expressed as a ratio
of the light intensity at 530 nm over 475 nm by substracting the
background signal, which was detected when the Rluc fusion
proteins were only expressed with pCDNA3.1. The BRET1 curve
was obtained by fitting the data points to a non-linear regression
equation assuming a single binding site using GraphPad Prism
version 6.00 (San Diego, CA, USA).
Patch-clamp experiments of astrocytes
Three days before the experiment, dB-cAMP-differentiated
astrocytes were trypsinized and seeded at a density of 1 − 3
× 104 cells onto 24-well plates containing a glass coverslip with
supplemented DMEM and 250 μM dBcAMP. The glass coverslip
was mounted on the stage of inverted microscopy equipped
with phase-contrast optics and fluorescence illumination. Patch
pipettes were pulled from borosilicate glass capillaries (Clark
Electromedical, UK) in a Flaming/Brown micropipettepuller P-
97 (Sutter instruments). The electrophysiological recordings
were performed with a patch clamp amplifier (Axopatch 200B,
Molecular Devices, Union City, CA). The electrodes had a
resistance of 4–5 MΩ when filled with intracellular solution
(in mm): 144 NMDG-Cl, 2 MgCl2, 5 EGTA, 5 HEPES, 5 Glucose with
pH 7.3 and 300 mOsm/kg.
To measure VRAC and ClC-2 currents, the extracellular solu-
tion contained (in mm): 144 NMDG-Cl, 2 CaCl2, 2 MgCl2, 5 HEPES,
5 glucose, with pH 7.3 and 300 mOsm/kg. For VRAC, hypotonic
extracellular solution (−25%) was obtained by decreasing the
NMDG-Cl concentration to 105 mm (220 mOsm/kg). For ClC-2,
the depolarizing extracellular solution contained (in mm): 144
NaCl, 11 KCl, 1.3 CaCl2, 0.4 MgSO2, 1.2 KH2PO4, 25 HEPES-NaOH,
10 glucose, with pH 7.2 and 300 mOsm/kg. All the solution
osmolarities were adjusted with sorbitol. An Ag/AgCl ground
electrode mounted in a 3 M KCl agar bridge was used. Membrane
currents were recorded in the whole-cell patch clamp configu-
ration, filtered at 2 kHz, digitized at 10 kHz and acquired with
pClamp 10 software (Molecular Devices). Data were analyzed
with Clampfit 10 (Molecular Devices) and Prism 4 (GraphPad
Software, Inc., La Jolla, CA). Whole-cell capacitance and series
resistance were compensated with the amplifier circuitry. Series
resistance was always kept below 10 MΩ and compensated at
70–80%. All recordings were performed at room temperature (22–
23◦C). Currents were evoked in 4 s pulses from −120 to +50 mV
(10 mV) to measure ClC-2 currents and from −80 to +80 mV
(20 mV) to measure VRAC currents. The holding potential was
0 mV.
Statistics
Statistical significance was assessed between two groups using
the unpaired or paired Student’s test as appropiate. For statistical
analyses of multiple groups, one-way analysis of variance and
multiple comparison’s test (Dunnet) versus control groups were
performed.
Supplementary Material
Supplementary Material is available at HMG online.
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